PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
(1) Background: Niraparib and Talazoparib are poly (ADP-ribose) polymerase (PARP) 1/2 inhibitors. It is assumed that combining PARP inhibitors with radiotherapy could be beneficial for cancer treatment. In this study, melanoma cells were treated with Niraparib and Talazoparib in combination with ion...
Main Authors: | Stephanie Jonuscheit, Tina Jost, Fritzi Gajdošová, Maximilian Wrobel, Markus Hecht, Rainer Fietkau, Luitpold Distel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/12/6/849 |
Similar Items
-
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
by: Verena Weigert, et al.
Published: (2020-08-01) -
Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
by: Dong Zhou, et al.
Published: (2021-05-01) -
Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
by: Jiaguo Li, et al.
Published: (2020-01-01) -
BET-inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
by: Francesco Paolo Fiorentino, et al.
Published: (2020-12-01) -
The Prognostic Values of PARP-1 Expression in Uveal Melanoma
by: Malgorzata Gajdzis, et al.
Published: (2021-01-01)